Drug intelligence / Profile preview

MTX-474

Development stage: Phase 2
Lead developer: Mediar Therapeutics
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral (intravenous Or Subcutaneous Injection)

Overview

MTX-474 is a first-in-class human IgG1 monoclonal antibody developed by Mediar Therapeutics. It is designed to neutralize EphrinB2 signaling, which plays a key role in the onset and progression of fibrosis. Ephrin ligands and their receptors are involved in biological processes such as cell migration, myofibroblast activation, and tissue remodeling—central mechanisms in fibrotic diseases. Preclinical evidence implicates EphrinB2 in the fibrosis of skin, lungs, and heart; its expression correlates with disease severity. MTX-474 is being developed primarily for systemic sclerosis (SSc) and other fibrosing conditions[1][2][3][4][7].

Other names: Anti-ephrinB2 humanized IgG1 monoclonal antibody (Mediar)

Targets

EFNB2 (Ephrin-B2)

Beyond the preview

Go deeper on MTX-474.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX-474.

Explore the full profile